Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Multiple Myeloma Physicians

Articles with lock require a subscription to GLG News | Request a free trial
April 18, 2008
XELOX=FOLFOX! Score one for Roche!
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
In MCRC FOLFOX which involves infusional 5FU has been the cornerstone of therapy. This study shows that an oral 5FU substitute, Xeloda, can replace the IV 5FU and expedide care and avoid cumbersome infusions.
Donald FlemingApril 16, 2008
Non small cell lung cancer has little to be excited about
Analysis of: ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Lilly will likely get front line approval for Alimta in non small cell lung cancer Most patients with advanced disease never see a response to therapy
April 15, 2008
Novartis initiated, positive in randomized phase II trial- I think they (we) may have something!
Analysis of: ASA404 begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death | www.pipelinereview.com
Author: GLG Expert Contributor
"ASA404 is a Tumor-Vascular Disrupting Agent (Tumor-VDA) that selectively causes the collapse of existing tumor blood supply leading to extensive tumor cell death." It is being combined with Taxol and carboplatin in a randomized phase III study.
April 15, 2008
Alimta (Lilly): Approved as First Line Agent in Europe for Non Squamous Cell Lung Ca!!!
Analysis of: ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Alimta will be used first line with Cis Platin as a primary therapy for non squamous non small cell lung cancer (NSCLCA)
April 14, 2008
Physician owned hospitals. Beneficial to whom? Certainly not the patient!!!
Analysis of: U.S. Reps give boost to physician-owned hospitals | www.fiercehealthcare.com
Author: GLG Expert Contributor
2 Texas U.S. Reps think that physcian owned hospitals are OK?
April 14, 2008
Co-Payments for Expensive Drugs Soar: Does Pharma really want governmental controls?
Analysis of: Co-Payments for Expensive Drugs Soar | www.nytimes.com
Author: GLG Expert Contributor
Co payments which had been $5/10/20 in the past are now a %age of the cost. When the cost may be upwards of $50-100K and you have a 20% co pay you can see the costs that are transfered back to the insured.
April 14, 2008
Genentech still has a lucrative drug pipeline , but may not meet zelous estimates.
Analysis of: Genentech Profit Jumps By 12% on Solid Revenue | online.wsj.com
Author: GLG Expert Contributor
Genetech has an impressive inventory of block-buster drugs: Avastin, Rituximab,  and Herceptin,  whose sales have been increasing on a regular base. Hereceptin and Avastin will be getting more and more use with new indications and longer dosing schedules. However, given the sagging economy...
April 14, 2008
Hematide: a long acting ESA with more potential in chronic renal failure than in chemotherapy induced anemia.
Analysis of: Affymax and Takeda Report Long-Term Safety and Effectiveness Data of Hematide in Chronic Renal Failure Patients With Anemia | pharmalive.com
Author: GLG Expert Contributor
Affymax's Hematide is a long acting synthetic peptide that stimulates erythropoietin and acts as an ESA. Together with Takeda, the company sponsored a phase II trial that showed safety and efficacy in patients with chronic renal failure; phase 3 trials are underway. This drug amy overtake the currently...
April 11, 2008
Genentech/Avastin: Drp in sales?? Be patient!
Analysis of: Genentech Profit Jumps By 12% on Solid Revenue | online.wsj.com
Author: GLG Expert Contributor
Has Avastin "hit the wall" as far as increased sales are concerned? Growth in the breast cancer market has not been as exuberant as expected.
April 10, 2008
Millennium purchase may open up avenues for more sales??
Analysis of: Takeda to Buy Millennium In $8.8 Billion Deal | online.wsj.com
Author: GLG Expert Contributor
Japan's biggest (by revenue) drug manufacturer has placed a bid For Millennium and it's primary product Velcade.

Previous Page : 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Next161 to 170 of 889

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617